Literature DB >> 16516167

Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion.

Jeong Hyun Lee1, So Youn Park, Yung Woo Shin, Ki Whan Hong, Chi Dae Kim, Sang-Min Sung, Ki Young Kim, Won Suk Lee.   

Abstract

In the present study, we elucidated effect of cilostazol to prevent the occurrence of vacuolation and rarefaction of the white matter in association with apoptosis induced by bilateral occlusion of common carotid arteries in the male Wistar rats. Rats orally received vehicle (DMSO) or 60 mg kg(-1) day(-1) (orally) cilostazol for 3, 7, 14 or 30 days. In the vehicle group, increased vacuolation and rarefactions in the white matter were accompanied by extensive activation of both microglial and astroglial cells with suppression of oligodendrocytes in association with increased TNF-alpha production, caspase-3 immunoreactivity and TUNEL-positive cells in the white matter including optic tract. Post-treatment with cilostazol (60 mg kg(-1) day(-1)) strongly suppressed not only elevated activation of astroglia and microglia but also diminished oligodendrocytes following chronic cerebral hypoperfusion. In conclusion, cilostazol (60 mg kg(-1) day(-1), orally) significantly reduced the apoptotic cell death in association with decreased TNF-alpha production and caspase-3-positive cells in the white matter of rat brains subjected to bilateral occlusion of common carotid arteries, consequently ameliorating vacuoles and rarefaction changes in the white matter.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516167     DOI: 10.1016/j.brainres.2006.01.088

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  22 in total

1.  Effects of chronic guanosine treatment on hippocampal damage and cognitive impairment of rats submitted to chronic cerebral hypoperfusion.

Authors:  Marcelo Ganzella; Enderson Dias Alves de Oliveira; Daniel Diniz Comassetto; Fernanda Cechetti; Victor Hermes Cereser; Júlia Dubois Moreira; Gisele Hansel; Roberto Farina Almeida; Denise Barbosa Ramos; Yanier Nuñes Figueredo; Debora Guerini Souza; Jean Pierre Oses; Paulo Valdeci Worm; Matilde Achaval; Carlos Alexandre Netto; Diogo Onofre Souza
Journal:  Neurol Sci       Date:  2011-12-14       Impact factor: 3.307

2.  Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.

Authors:  Shu-Yu Tai; Chen-Yu Chien; Yu-Han Chang; Yuan-Han Yang
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

3.  Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.

Authors:  Jun-Young Lee; Haewoo Lee; Hye Bin Yoo; Jung-Seok Choi; Hee-Yeon Jung; Eun Jin Yoon; Hongrae Kim; Ye-Ha Jung; Ho-Young Lee; Yu Kyeong Kim
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

Review 4.  Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.

Authors:  Robert B Cameron; Craig C Beeson; Rick G Schnellmann
Journal:  J Med Chem       Date:  2016-09-27       Impact factor: 7.446

5.  High-Mobility Group Box 1 Neutralization Prevents Chronic Cerebral Hypoperfusion-Induced Optic Tract Injuries in the White Matter Associated with Down-regulation of Inflammatory Responses.

Authors:  Yue Hei; Xin Zhang; Rong Chen; Yuefei Zhou; Dakuan Gao; Weiping Liu
Journal:  Cell Mol Neurobiol       Date:  2019-06-13       Impact factor: 5.046

6.  AT1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion.

Authors:  Veysel Haktan Ozacmak; Hale Sayan; Alpay Cetin; Aysenur Akyildiz-Igdem
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

7.  An oral formulation of cilostazol nanoparticles enhances intestinal drug absorption in rats.

Authors:  Chiaki Yoshioka; Yoshimasa Ito; Noriaki Nagai
Journal:  Exp Ther Med       Date:  2017-10-24       Impact factor: 2.447

8.  Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.

Authors:  Jian-Jun Guo; En Xu; Qing-Yuan Lin; Guo-Ling Zeng; Hai-Feng Xie
Journal:  Neurosci Bull       Date:  2009-12       Impact factor: 5.203

Review 9.  Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.

Authors:  Jeong Hyun Lee; So Youn Park; Hwa Kyoung Shin; Chi Dae Kim; Won Suk Lee; Ki Whan Hong
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

10.  Neuroprotective Effects of Simvastatin and Cilostazol in L-Methionine-Induced Vascular Dementia in Rats.

Authors:  Ahmed M El-Dessouki; Mai A Galal; Azza S Awad; Hala F Zaki
Journal:  Mol Neurobiol       Date:  2016-08-20       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.